Mogelijk gemaakt door 
Translate
Translate
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6-10 in Los Angeles. The Company’s therapies and technologies for drug-resistant epilepsy treatment will be featured in numerous scientific posters to support a deeper understanding of the non-pharmacological treatment of seizures. LivaNova will also present in-progress data from its contemporary real-world evidence study, “CORE-VNS: Comprehensive Outcomes Registry in Subjects With Epilepsy Treated With Vagus Nerve Stimulation Therapy.”
“Accelerating access to care and improving quality of life for epilepsy patients around the world are key priorities for LivaNova,” said Stephanie Bolton, President, Global Epilepsy at LivaNova. “These poster presentations, which share interim data from our CORE-VNS study as well as other clinical and health economic research, showcase our enduring commitment to advancing epilepsy research.”
The scientific poster presentations feature the research work of LivaNova employees and/or independent investigators. Conference attendees will have an opportunity to view posters during the 2024 AES Annual Meeting on Saturday, December 7 and Sunday, December 8, with presentations by authors from 12:00 – 2:00 p.m. PST each day. Posters will also be on display in the LivaNova Scientific Exhibit on Monday, December 9 from 8:00 – 11:00 a.m. PST.
Abstracts and poster times can be found at the American Epilepsy Society website.
Saturday, December 7
INTENDED USE/INDICATIONS FOR USE– UNITED STATES
The VNS Therapy™ System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding participation in upcoming events, clinical research, and the treatment of drug-resistant epilepsy with VNS Therapy™. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204503430/en/
LivaNova Investor Relations and Media Contacts +1 281-895-2382 Briana Gotlin VP, Investor Relations InvestorRelations@livanova.com Deanna Wilke VP, Corporate Communications Corporate.Communications@livanova.com
Source: LivaNova PLC
